Logo

Genentech

Sangamo, Genentech Ink Deal to Advance Genomic Medicines for Alzheimer's, Other Neurological Diseases

Sangamo exclusively licensed certain technology to Genentech, which it will use to develop tau-directed medicines.

European Commission Approves Alecensa as Adjuvant Treatment for ALK-Positive Lung Cancer

Treatment with Alecensa after surgery reduced the risk of recurrence or death by 76 percent compared to chemo in patients with early-stage ALK-positive lung cancer.

FDA Grants Priority Review to Genentech's Inavolisib NDA in Breast Cancer

The agency is slated to decide in November whether to approve the PI3Kα inhibitor as a first-line option for PIK3CA-mutated advanced breast cancer.

In Brief This Week: AstraZeneca, Genentech, Achilles, Bristol Myers Squibb, Roche, Anixa Biosciences

News items for the week of May 20, 2024.

AI Tool Shows Promise in Cancer Therapy Matching, but More Training Data Needed
Premium

Researchers call for more data sharing from single-cell RNA sequencing studies to help validate machine learning precision medicine tools.

May 10, 2024

Chinese Trial Suggests PARP, VEGF Inhibitor Combo Benefits Advanced BRCA1/2-Mutant Breast Cancer
Premium

May 2, 2024

Nykode Therapeutics Pursuing Fast-to-Market Strategy for HPV16-Targeted Cancer Vaccine
Premium

Apr 19, 2024

FDA Approves Genentech's Alecensa as Adjuvant Treatment for ALK-Positive Lung Cancer

Apr 16, 2024

Genentech, Adaptimmune End Collaboration, License Agreement for T-Cell Receptor Therapies

Apr 8, 2024

BioNTech, Roche's Bespoke Pancreatic Cancer Vaccine Demonstrates Lasting Responses in Early Trial
Premium

Apr 3, 2024

Gritstone Bio Eyes Pivotal Trial for Personalized Cancer Vaccine as Early ctDNA Endpoint Disappoints
Premium

Mar 14, 2024

NCI-MATCH Analysis Suggests Dual HER2 Therapy Activity Beyond Breast, Gastric Cancer
Premium

Jan 23, 2024

Roche Ends Collaboration With AC Immune on Two Alzheimer's Drugs

Jan 23, 2024

Roche's Genentech to Pay $15M Upfront to GenEdit in Autoimmune Disease Drug Development Collab

Dec 12, 2023

Circulating Tumor DNA Helps ID First-Line Lymphoma Patients for Roche's Columvi, R-CHOP

Dec 7, 2023

Tukysa-Kadcyla Combo Shows Efficacy in HER2-Positive Breast Cancer Patients With Brain Metastases
Premium

Dec 5, 2023

Bolt Biotherapeutics Studying BDC-1001 With Genentech's Perjeta in HER2-Positive Breast Cancer

Nov 16, 2023

FDA Approves BMS's Augtyro for Advanced ROS1-Positive NSCLC

Oct 21, 2023

Roche's Alecensa Lowers Recurrence in Adjuvant NSCLC, But Experts Await Overall Survival Data
Premium

Oct 20, 2023

PD-L1 Expression Crucial to HER2-Positive Gastric Cancer Outcomes on Keytruda, Herceptin, Chemo
Premium

Oct 19, 2023

BioNTech to Study mRNA Cancer Vaccine as Adjuvant Pancreatic Cancer Treatment in Phase II Trial

Oct 18, 2023

Breast Cancer Study Informs Affibody, GE HealthCare's Development Path for HER2 Radiopharmaceutical
Premium

Sep 5, 2023

Nykode Therapeutics Cleared to Begin Phase II Trial of Vaccine, Tecentriq in Cervical Cancer

Aug 29, 2023

European Commission Approves Keytruda, Herceptin, Chemo for HER2-, PD-L1-Positive Gastric Cancer

Aug 9, 2023

FDA Converts Gavreto Accelerated Approval to Full Approval in RET Fusion-Positive NSCLC